BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q1 2024 vs. Q4 2023
How the institutions holding BIO-TECHNE Corp changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 532 | 5 | 556 | +29 |
| Shares | 155.5M | 15.8K | 158.6M | +3.15M (+2.0%) |
| Value | $12.0B | $1.22M | $11.2B | −$827.7M (−6.9%) |
5 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (73)
Institutions that held BIO-TECHNE Corp at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (44)
Institutions that held BIO-TECHNE Corp at the end of Q4 2023 and filed for Q1 2024 without it.
Not filed for Q1 2024 yet (5)
Institutions that held BIO-TECHNE Corp at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Focus Financial Network Inc | 11,792 | $909.9K |
| Sawtooth Solutions, LLC | 2,803 | $216.3K |
| Baystate Wealth Management LLC | 500 | $38.6K |
| Desjardins Global Asset Management Inc. | 485 | $37.4K |
| Bartlett & Co. LLC | 172 | $13.0K |